Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in Neovascular AMD (PANDA-2)
NCT03630952Phase 3
Key facts
- Status
- Terminated
- Start
- Dec 2018
- Primary completion
- Sep 2020
- Countries
- 12
- Modality
- Fc-Fusion Proteins
- Drugs
- conbercept
- Conditions
- neovascular age-related macular degeneration (NVAMD)
01
Overview
Phase 3, randomised, double-blind trial of conbercept in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Mean change from baseline in best corrected visual acuity at 36 weeks. Started Dec 2018; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 50 or older with active subfoveal choroidal neovascularization secondary to AMD, who are treatment-naïve and have a BCVA of 78-25 letters.
04
Endpoints
Primary
Mean change from baseline in best corrected visual acuity
Secondary
Proportion of subjects maintaining vision
Proportion of subjects gaining >=15 letters
Mean change from baseline in central retinal thickness
Mean change from baseline in ETDRS BCVA letter score at Week 96
Number of participants with adverse events
Blood concentration of conbercept
Presence of anti-drug antibody
Beyond the preview
Go deeper on NCT03630952.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630952.